Beijing Bioocus Medical Group

• Pioneering Research: At Bioocus, we are at the forefront of cellular immunotherapy research, constantly developing new and more effective treatments.

• Integrated Value Chain: From research and development to clinical application, our integrated approach ensures seamless and high-quality care.

• State-of-the-Art Facilities: Our GMP-certified facilities guarantee the highest standards in safety and efficacy for all our therapies, crucial for a cancer treatment hospital in China.

• Extensive Network: Our collaborations with top universities, research institutes, and over 20 leading hospitals globally mean you get access to a vast pool of medical expertise.

• Patient-Centric Care: We are dedicated to providing personalized, high-quality treatment solutions tailored to each patient's unique needs.

• CAR-T Cell Therapy: A revolutionary treatment that re-engineers a patient's own immune cells to powerfully fight cancer.

• TILs Therapy (Tumor-Infiltrating Lymphocytes): Utilizing the body's natural tumor-fighting cells, expanded and enhanced for a targeted attack.

• NK Cells Therapy (Natural Killer Cells): Harnessing the potent natural killer cells of the immune system to identify and destroy cancerous or infected cells.

• Gene Therapy: Modifying genes to treat or prevent disease by correcting underlying genetic problems.

• Advanced Therapies for Refractory Diseases: Offering hope and effective solutions for conditions that have not responded to conventional treatments.

• Continuous Innovation: Investing heavily in R&D to bring the next generation of cellular and gene therapies to our patients.

• Global Collaboration: Partnering with leading medical institutions worldwide to share knowledge and advance treatment protocols.

• Patient Safety and Efficacy: Adhering to the strictest international standards to ensure all treatments are both safe and highly effective.

• Comprehensive Support: Providing extensive support throughout your treatment journey, from initial consultation to post-treatment care.

• We maintain a wide network of CGT centers for accessibility.

• Collaboration with top universities ensures cutting-edge research informs our practice.

• Partnerships with over 20 leading hospitals globally expand our reach and expertise.

• International Patient Services:  End-to-end support from consultation to hospitalization, including a streamlined flowchart for patient guidance.

• Strategic Partnerships: Collaborations with 48 top-tier hospitals across China and regional offices in Hong Kong, South Korea, India, Pakistan, the Middle East, Mongolia, Egypt, and South Africa. Partnerships with health authorities and embassies further enhance global outreach.

• Online Consultation & Case Evaluation: Patients engage with multilingual medical coordinators via website or hotline for personalized consultation. Preliminary treatment plans, expert online assessments, and remote consultations are arranged.

• Hospital Admission & Visa Assistance: Medical coordinators schedule treatment timelines and assist with visas, flights, and accommodations.

• Hospitalization & Treatment: 24/7 airport pickup and dedicated multilingual service coordinators provide full language and logistical support. Post-admission, comprehensive diagnostics confirm final treatment protocols.

• Post-Treatment Follow-Up: Tailored rehabilitation guidance, long-term monitoring, and telemedicine ensure continuity of care. 

• B-cell acute lymphoblastic leukemia

• Multiple myeloma

• Chronic lymphocytic leukemia

• Non-Hodgkin lymphoma

• Diffuse large B-cell lymphoma

• SLE?Systemic Lupus Erythematosus?

• Myasthenia gravis

• Other autoimmune diseases

1. Personalized Treatment: Each CAR-T therapy is customized to the patient, ensuring highly targeted and effective treatment outcomes.

2. Diverse Targeting Options: With a wide range of target antigens, including CD7, CD19, CD20, CD22, and BCMA, our CAR-T products offer unparalleled versatility in treating various hematological malignancies and autoimmune diseases.

3. Proven Clinical Success: Our CAR-T therapies have demonstrated exceptional effectiveness across numerous clinical cases, with impressive remission rates and safety profiles, reinforcing our position as a leader in immunotherapy.

4. High Cost-Effectiveness: We offer a competitive edge with superior quality treatments at more accessible pricing compared to other CAR-T products on the market.

5. Cutting-Edge Technology: Leveraging the latest advancements in genetic engineering, our CAR-T therapies embody the future of cancer and autoimmune disease treatment.

6. Expert Clinical Support: Our experienced team of clinicians and researchers provides comprehensive care from initial consultation through therapy administration and follow-up.

• High specificity: tumor specific T cells sensitized by tumor antigens, recognized by multiple TCRs

• Strong tropism: high expression of chemokine receptors, strong tumor tropism, and faster action

• Killing tumors: TILs are activated and amplified to 109-1011, and residual cancer cells are cleared after surgery

• Continuous effect: The proportion of memory T cells is high, and they can survive in the body for a long time and be continuously monitored

• High safety: extraction, amplification, no rejection reaction, and SAE of TILs cells from patients themselves

• NSCLC(non-small cell lung cancer)

• Melanoma

• Breast Cancer

• Cervical Cancer

• Ovarian Cancer.

1. TILs are the patient's own cells, so there is no risk of rejection, ensuring high safety.

2. Adverse reactions: Fever is common (due to the release of cytokines during TILs cell-mediated tumor clearance, causing transient fever, usually requiring no specific treatment and resolving on its own).

3. Other adverse reactions reported in studies include thrombocytopenia, febrile neutropenia, hypertension, etc., mostly attributed to TILs in combination with other drugs such as pre-treatment chemotherapy (cyclophosphamide + fluorouracil), high-dose IL-2, PD-1 monoclonal antibodies, etc.

1. Hemo-cel, a groundbreaking gene therapy offering new hope for patients suffering from sickle cell disease (SCD) and transfusion-dependent thalassemia (TDT)

What is Hemo-cel?

Hemo-cel is an advanced therapy that uses the patient’s own hematopoietic stem and progenitor cells (HSPCs), which are genetically modified to produce healthy hemoglobin. By correcting the faulty gene responsible for the blood disorder, Hemo-cel can dramatically improve patients' lives, potentially eliminating the need for regular blood transfusions and offering a lifelong solution.

How Does Hemo-cel Work?

The treatment process begins by collecting HSPCs from the patient’s blood. These cells are then enhanced outside the body using a lentiviral vector that introduces a modified β-globin gene. Once the cells are ready, they are reinfused back into the patient, where they begin to generate healthy red blood cells capable of producing functional hemoglobin. This process restores the balance between α-globin and β-globin chains in the blood, effectively reducing the symptoms of anemia and allowing the patient to achieve transfusion independence.

Proven Results

Clinical trials of Hemo-cel have shown remarkable success:

• 100% of patients in the trial achieved successful bone marrow engraftment.

• Most patients became transfusion-independent within weeks after the therapy.

• One patient has been transfusion-free for nearly four years without any significant side effects.

• The therapy also helps alleviate iron overload, a common complication in TDT patients who undergo regular transfusions.

2. Nusinersen Sodium Injection: The Hope for Spinal Muscular Atrophy

Nusinersen Sodium Injection is a revolutionary treatment for Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder that causes motor neuron loss, leading to severe muscle atrophy and weakness. As the world’s first approved disease-modifying therapy for 5q SMA, it has transformed patient outcomes globally

• Nusinersen Sodium is an antisense oligonucleotide (ASO) therapy that targets the SMN2 gene.

• By modifying its splicing process, it boosts the production of functional SMN protein, essential for motor neuron survival and function.

• The drug is administered directly into the cerebrospinal fluid via lumbar puncture, ensuring it reaches the affected areas effectively.

SMA Type I:

• Increases 2-year survival rates from a historical 50% to over 80%.

• Enhances motor functions like independent sitting and head control.

• Reduces dependency on ventilators.

SMA Type II and III:

• Slows disease progression.

• Maintains or improves limb mobility and respiratory function.

• Pre-symptomatic treatment (e.g., in newborns) can lead to near-normal motor development.

Long-Term Impact:

• Five-year follow-up data show stable motor function improvements with no significant decline.

Global Reach:

• Since its FDA approval in 2016, over 100,000 patients across 60+ countries have benefited, covering all SMA types.

Evidence from Research

Clinical trials (e.g., EMBRACE, ENDEAR, CHERISH) involving 274 patients demonstrate significant improvements:

• Motor milestone response: 51% better than control groups (p less than 0.00001).

• HINE-2 score improvement: 26% better than controls (p less than 0.0003).

• Studies in adolescents and adults also show enhanced motor function scores (e.g., HFMSE, RULM) after 26 months.)

Education & International Experience

• Studied and worked at Winship Cancer Institute of Emory University School of Medicine from 2000 to 2008

• Extensive experience in standardized tumor treatment, specializing in early diagnosis of lung cancer, chemotherapy, targeted therapy, and anti-angiogenic therapy

• Executive Editorial Board Member of Chinese Journal of Lung Cancer

• Editorial Board Member of Tianjin Medicine, International Journal of Oncology, and International Respiratory Journal

Professional Memberships & Leadership Roles

• Member of Chinese Medical Association Oncology Branch, Lung Cancer Group of Respiratory Branch of Chinese Medical Association, and Oncology Group of Chinese Geriatrics Society

• Vice Chairman of Palliative Medicine Committee of Beijing Oncology Society, Oncology Specialty Committee of Tianjin Medical Experts Committee, and Precision Medicine Specialty Committee of Tianjin Physicians Association

• Leader of Lung Cancer Specialty Group of Tianjin Targeted Specialty Committee of China Anti-Cancer Association

• Head of Lung Cancer Specialized Group of Tianjin Targeted Specialized Committee of Chinese Anti-Cancer Association

Professional Titles

• Vice President of Tianjin Medical University General Hospital

• Director of Hematology Medical Center

• Director of Tianjin Clinical Medical Research Center for Hematological Diseases

• Director of Tianjin Key Laboratory for Prevention and Treatment of Bone Marrow Failure and Carcinoma Hematopoietic Cloning

• Director of Tianjin Hematology Research Center

Teaching & Academic Contributions

• Course Leader of Internal Medicine for Tianjin Municipal First-Class Course

• Model Course Instructor for Civics and Politics at Tianjin Municipal Courses

• Honored as "Top Ten Doctors" of Tianjin Medical University

• Awarded “Outstanding Communist Party Member” and “Heroine of Women” at Tianjin Medical University

• Recognized as "Excellent Teacher" of Tianjin Medical University

Experiences and Specializations

• Director of the Department of Hematology

• Director of the Internal Medicine Teaching and Research Department

Leadership & Committee Memberships

• Vice Chairman of the Hematology Branch of the Chinese Medical Association

• Vice Chairman of the Hematologists Branch of the Chinese Medical Association

• Chairman-elect of the Hematology Immunology Branch of the Chinese Immunology Society

• Chairman of the Clinical Flow Cytometry Group

• Standing Committee Member of the Tianjin Medical Association

• Chairman of the Hematology Branch of the Tianjin Medical Association

• Chairman of the Clinical Blood Transfusion Committee of the Tianjin Blood Transfusion Association

• Member of the Standing Committee of the Chinese Society of Cancer Organizations (CSCO)

• Director of the Chinese Blood Transfusion Association

• Medical Accident Appraisal Expert of the Chinese Medical Association

• Member of the China Medical Science and Technology Award Evaluation Committee

• Member of the Clinical Application of Pharmaceutical Biotechnology Committee of the China Pharmaceutical and Biotechnology Association (CPBTA)

• Member of the Gerontological Society of Geriatric Oncology Committee

• Clinical Pathway Technical Audit Expert for the Ministry of Health (MOH)

• Clinical Application of Medical Technology Audit Expert for Tianjin Municipality

• Overseas Member of the American Society of Hematology

Education & Experience

• Graduated from Tianjin Medical University in 1982

• Over 30 years of experience in clinical practice, teaching, and research

• Specializes in respiratory medicine and oncology at the General Hospital of Tianjin Medical University

Leadership & Committee Memberships

• Deputy Director of the Respiratory Branch of Tianjin Society of Chinese and Western Medicine, Chinese Medical Association

• Standing Committee Member of the Tumor Psychology Committee, Tianjin Anti-Cancer Association

• Member of the Tianjin Society of Psychosomatic Medicine, Chinese Medical Association

• Head of Tianjin Tumor Pain Group, Tianjin Psychosomatic Medicine, Chinese Medical Association

• Member of the Tumor Clinical Chemotherapy Committee, Chinese Anti-Cancer Association

Professional Leadership & Contributions:

• Director, Tianjin Institute of Oncology

• Director, National Clinical Research Center for Cancer

• Member, Ninth National Committee, Chinese Association for Science and Technology

• Member, Chinese Academy of Medical Sciences

• Editor-in-Chief, Chinese Journal of Clinical Oncology & Cancer Biology & Medicine

Current Positions:

• Academician, Chinese Academy of Engineering

• Director, Tianjin Cancer Institute

• Director, National Clinical Research Center for Malignant Tumors

• Honorary Chairman, Chinese Anti-Cancer Association

• Vice President, International Society for Breast Disease

Expertise & Innovations:

• Precise diagnosis & meticulous surgical techniques

• Radical surgery for malignant pancreatic tumors

• Minimally invasive laparoscopic and localized treatments

• Functional-preserving surgeries for low-grade and benign tumors

Current Roles:

• Director, Tianjin Airport Hospital & Tianjin Cancer Hospital

• Chief Physician, Professor, Doctor, Doctoral Supervisor

• Standing Director, Chinese Anti-Cancer Association

• Chairman, Tianjin Anti-Cancer Association

• Incoming Chairman, Precision Medicine Professional Committee, Chinese Anti-Cancer Association

• Vice Chairman, Pancreatic Cancer Professional Committee, Chinese Anti-Cancer Association

• Vice Chairman, Hepatobiliary and Pancreatic Surgery Committee, Chinese Medical Education Association

• Executive Editor, Cancer Biology & Medicine, Chinese Journal of Clinical Oncology

Experiences and Specializations:

• Director, Hematology Department, Tianjin Medical University Cancer Hospital

• Leader, Blood Transplantation Department, Airport Hospital, Tianjin Cancer Hospital

• Botanic Physician, Doctor of Medicine (M.D.), Master's Thesis Supervisor

• Practicing at: Beijing Bioocus International Medical Center

Professional Affiliations:

• Member, Hematology Professional Committee, Chinese Anti-Cancer Association

• Member, Myeloma Professional Committee, Chinese Society of Clinical Oncology

• Deputy Director, Plasma Cell Society of China Health Promotion Association

• Member, Hematology Rehabilitation Committee, Chinese Society of Rehabilitation Medicine

• Member, Hematology Branch, Chinese National Medical Association

• Member, Hematology Professional Committee, Chinese Society of Integrated Traditional and Western Medicine

• Deputy Director, Hematology and Oncology Professional Committee, Tianjin Anti-Cancer Association

• Deputy Director, Bone and Soft Tissue Professional Committee, Tianjin Anti-Cancer Association

• Standing Director, Tianjin Health Education Association

• Standing Director, Tianjin Medical and Health Society

Experiences and Specializations

• Director of Breast Oncology Department

• Chief physician, Doctor of Medicine(M.D.)

• Masters thesis supervisor

• Standing member of the Vascular and Endovascular Surgery Committee of Tianjin Health Education Association

Professional Titles & Affiliations:

• Director of the Department of Gastric and Colorectal Tumors

• Chief Physician, Doctor of Medicine (M.D.)

• Standing Committee Member, Department of Gastroenterology, China International Association for the Promotion of Medical and Health Care

• Member, Colorectal Cancer Professional Committee & Abdominal Professional Group, Sarcoma Professional Committee, Chinese Anti-Cancer Association

• Member, Colorectal Surgery Group, Chinese Medical Doctor Association

• Vice Chairman, PPS Branch, China NOSES Alliance

• Standing Member, Elderly Tumor Committee, Tianjin Anti-Cancer Association

• Editorial Board Member, Chinese Journal of Clinical Physicians, Chinese Electronic Journal of Colorectal Diseases, Colorectal Anus

Expertise & Specialization:

• Low and ultra-low rectal cancer surgery with a focus on preserving anal function

• Comprehensive treatment of colorectal cancer with liver metastasis

• Radical resection of colon cancer using standard mesentery resection

• Complex colorectal cancer surgeries

When people visit Beijing for medical care, they also get a chance to explore its amazing sights. One of the most famous places is the Great Wall of China. It’s a giant wall that was built long ago and offers breathtaking views. Another must-see place is the Forbidden City, where old Chinese emperors used to live. It has beautiful buildings and a lot of history. The Temple of Heaven is another peaceful spot where visitors can see ancient Chinese architecture and enjoy quiet gardens.

People who come to Beijing for stem cell therapy don’t just get medical treatment—they also experience an exciting journey. They get to see famous historical places, learn about Chinese culture, and enjoy modern attractions. Beijing offers both top-quality healthcare and a chance to explore a beautiful city. This makes the trip not only helpful for their health but also a wonderful adventure they will never forget.